Incidence of Hypocalcemia in Patients with Post-Menopausal Osteoporosis or Cancer Skeletal Related Events after Denosumab in Comparison to Zoledronic Acid in a Community Hospital Setting

Abstract

Introduction: Denosumab, a monoclonal antibody, was recently approved by US Food and Drug Administration for treatment of postmenopausal osteoporosis and cancer skeletal related events (SRE). A variable incidence of hypocalcemia (5.5-13%) has been reported with denosumab as compared to the commonly used bisphosphonate, zolendronic acid (3.4-6%).